Vertaling van "for pregabalin--results from " (Frans → Nederlands) :

Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.
Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin‐‐results from the Swedish spontaneous adverse drug reaction reporting system.

Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P et Versavel M. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P en Versavel M. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neurlagia: results of a randomised, placebo-controlled clinical trial.

Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties related to the acquisition of King by Pfizer that could cause results to differ from expectations include: uncertainties as to the timing of the merger; the possibility that a governmental entity may prohibit or delay the consummation of the merger; and the risk of shareholder litigation, including the disposition of currently pending litigation, in connection with the merger.
Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties.

The graphs „Medical treatment‰ and „trial centres‰ show the results of the ACST/ACAS trials (expressed as constant hazards of stroke or death from the trials and age dependent hazards of all other cause mortality from the Flemish male life table at age 70 in the year 2000). 18 Intervention starts with a short period of high (peri-procedural) mortality, but the lower post-procedural hazard of death will overtake the higher hazard of medical treatment.
The graphs „Medical treatment‰ and „trial centres‰ show the results of the ACST/ACAS trials (expressed as constant hazards of stroke or death from the trials and age dependent hazards of all other cause mortality from the Flemish male life table at age 70 in the year 2000).[18] Intervention starts with a short period of high (peri-procedural) mortality, but the lower post-procedural hazard of death will overtake the higher hazard of medical treatment.

73. Schentag JJ et al : Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, thé infectious disease division and thé microbiology laboratory.
73. Schentag JJ et al: Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division and the microbiology laboratory.

[5] C. Chaix-couturier, I. Durand-zaleski, D. Jolly, and P. Durieux, Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues, Sante, vol. 12, no. 2, pp. 133-142, 2000.
[5] C. Chaix-couturier, I. Durand-zaleski, D. Jolly, and P. Durieux, Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues, Sante, vol. 12, no. 2, pp.

Results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30
Results from a national registry Am J Respir Crit Care Med 2006; 173: 1023-30

- Reeves WC, Heim C, Maloney EM, Youngblood LS, Unger ER, Decker MJ et al. Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results from a population-based study.
- Reeves, W. C. , C. Heim, et al (2006)" . Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results from a population-based study" .

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

results from the 1995 national postal survey of community pharmacies in England and Wales.
Methadone to opiate addicts. results from the 1995 national postal survey of community pharmacies in England and Wales.